Trial intelligence / Profile preview

Preemptive management of panitumumab-induced skin toxicity in RAS wild-type metastatic colorectal cancer

2010-022938-85Phase 2Completed

Sponsor
AIO-Studien
Start
Apr 2011
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 2, randomised trial of panitumumab in colorectal cancer (CRC) (2 arms), sponsored by AIO-Studien. Started Apr 2011; status: completed.

02

Drugs

panitumumab
03

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on 2010-022938-85.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022938-85.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call